HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 294/2/L152    most recent 00313.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moore, B. B. Articles by Hogaboam, C. M. Search for Related Content PubMed PubMed Citation Articles by Moore, B. B. Articles by Hogaboam, C. M.

INVITED REVIEW

ANIMAL MODELS OF HUMAN LUNG DISEASE

Murine models of pulmonary fibrosis

Departments of ¹Internal Medicine and ²Pathology, University of Michigan Medical School, Ann Arbor, Michigan

Human pulmonary fibrosis is characterized by alveolar epithelial cell injury, areas of type II cell hyperplasia, accumulation of fibroblasts and myofibroblasts, and the deposition of extracellular matrix proteins. The result is a progressive loss of normal lung architecture and impairment in gas exchange. Pertinent features of the human disease include temporal heterogeneity of the fibrotic lesions, progressive nature of the disease, development of fibrotic foci, and in some patients, a rapid worsening of symptoms known as an acute exacerbation. No current animal model recapitulates all of these cardinal manifestations of the human disease. However, investigations using murine models have led to the identification of many pathological cells and mediators that are believed to be important in human disease as well. In this review, we will summarize the characteristics, advantages, and disadvantages of many of the currently utilized murine models of pulmonary fibrosis.

pathological cells; mediators

This article has been cited by other articles:

				W. D. Hardie, S. W. Glasser, and J. S. Hagood Emerging Concepts in the Pathogenesis of Lung Fibrosis Am. J. Pathol., July 1, 2009; 175(1): 3 - 16. [Abstract] [Full Text] [PDF]

				S. S. Iyer, A. M. Ramirez, J. D. Ritzenthaler, E. Torres-Gonzalez, S. Roser-Page, A. L. Mora, K. L. Brigham, D. P. Jones, J. Roman, and M. Rojas Oxidation of extracellular cysteine/cystine redox state in bleomycin-induced lung fibrosis Am J Physiol Lung Cell Mol Physiol, January 1, 2009; 296(1): L37 - L45. [Abstract] [Full Text] [PDF]

				F. Drakopanagiotakis, A. Xifteri, V. Polychronopoulos, and D. Bouros Apoptosis in lung injury and fibrosis Eur. Respir. J., December 1, 2008; 32(6): 1631 - 1638. [Abstract] [Full Text] [PDF]

				R. M. Jackson and C. D. Fell Etanercept for Idiopathic Pulmonary Fibrosis: Lessons on Clinical Trial Design Am. J. Respir. Crit. Care Med., November 1, 2008; 178(9): 889 - 891. [Full Text] [PDF]

				S. Hashimoto, F. Amaya, H. Matsuyama, H. Ueno, S. Kikuchi, M. Tanaka, Y. Watanabe, M. Ebina, A. Ishizaka, S. Tsukita, et al. Dysregulation of lung injury and repair in moesin-deficient mice treated with intratracheal bleomycin Am J Physiol Lung Cell Mol Physiol, October 1, 2008; 295(4): L566 - L574. [Abstract] [Full Text] [PDF]

				G. Matute-Bello, C. W. Frevert, and T. R. Martin Animal models of acute lung injury Am J Physiol Lung Cell Mol Physiol, September 1, 2008; 295(3): L379 - L399. [Abstract] [Full Text] [PDF]

				J. Gauldie and M. Kolb Animal models of pulmonary fibrosis: how far from effective reality? Am J Physiol Lung Cell Mol Physiol, February 1, 2008; 294(2): L151 - L151. [Full Text] [PDF]